Expertise in
18
conditions

Dr. Farzad Rahaghi

Pulmonary Medicine
Office
2950 Cleveland Clinic Blvd Fl 3, 
Weston, FL 
Offers Telehealth
Expertise in
18
conditions
Office
2950 Cleveland Clinic Blvd Fl 3, 
Weston, FL 

Overview

Farzad Rahaghi is a Pulmonary Medicine provider in Weston, Florida. Dr. Rahaghi is highly rated in 18 conditions, according to our data. His top areas of expertise are Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency (AATD), Interstitial Lung Disease, Lung Transplant, and Vertebroplasty.

His clinical research consists of co-authoring 46 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Pulmonary Medicine

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Office
2950 Cleveland Clinic Blvd Fl 3, Weston, FL 33331

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Completed
Publish Date: February 06, 2026
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH)
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH)
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drug: Ifetroban
Study Phase: Phase 2
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Completed
Publish Date: June 10, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
A Phase 3/4 Study to Evaluate the Safety, Immunogenicity, and Effects on the Alpha1-Proteinase Inhibitor (A1PI) Levels in Epithelial Lining Fluid Following Glassia Therapy in A1PI-Deficient Subjects
A Phase 3/4 Study to Evaluate the Safety, Immunogenicity, and Effects on the Alpha1-Proteinase Inhibitor (A1PI) Levels in Epithelial Lining Fluid Following Glassia Therapy in A1PI-Deficient Subjects
Enrollment Status: Completed
Publish Date: October 14, 2021
Intervention Type: Biological
Study Phase: Phase 3
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Enrollment Status: Completed
Publish Date: February 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

46 Total Publications

A Perspective on Referral and Selection for Pediatric Lung Transplantation.
A Perspective on Referral and Selection for Pediatric Lung Transplantation.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Published: August 05, 2025
Similar Doctors
Expertise in
24
conditions
Dr. David Zisman
Pulmonary Medicine
Expertise in
24
conditions
Dr. David Zisman
Pulmonary Medicine

Cleveland Clinic Florida

2950 Cleveland Clinic Blvd, 
Weston, FL 
 (0.1 miles away)
877-463-2010
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Zisman is a Pulmonary Medicine provider in Weston, Florida. Dr. Zisman is highly rated in 24 conditions, according to our data. His top areas of expertise are Acute Interstitial Pneumonia, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Hypersensitivity Pneumonitis, and Lung Transplant.

Jinesh Mehta
Expertise in
21
conditions
Dr. Jinesh Mehta
Pulmonary Medicine | Intensive Care Medicine
Expertise in
21
conditions
Dr. Jinesh Mehta
Pulmonary Medicine | Intensive Care Medicine

Egil And Pauline Braathen Center/Maroone Cancer Center

2950 Cleveland Clinic Boulevard, 
Weston, FL 
 (0.1 miles away)
877-463-2010
Languages Spoken:
English, Gujarati , Hindi
See accepted insurances
Offers Telehealth

Jinesh Mehta is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Weston, Florida. Dr. Mehta is highly rated in 21 conditions, according to our data. His top areas of expertise are Pulmonary Hypertension, Interstitial Lung Disease, Acute Interstitial Pneumonia, Emphysema, and Advanced Bronchoscopy.

Expertise in
28
conditions
Dr. Elio Donna
Pulmonary Medicine
Expertise in
28
conditions
Dr. Elio Donna
Pulmonary Medicine

Umhc-Sylvester Comprehensive Cancer Center

1475 NW 12th Ave, 
Miami, FL 
 (22.3 miles away)
305-243-6387
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Elio Donna is a Pulmonary Medicine provider in Miami, Florida. Dr. Donna is highly rated in 28 conditions, according to our data. His top areas of expertise are Lymphofollicular Hyperplasia, Lung Metastases, Lung Cancer, Acute Interstitial Pneumonia, and Advanced Bronchoscopy.

Frequently Asked Questions about Dr. Farzad Rahaghi

How do I make an appointment with Dr. Farzad Rahaghi?

You can book an appointment with Dr. Farzad Rahaghi by calling their office at 954-659-5450. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Farzad Rahaghi a top-rated expert for Pulmonary Hypertension?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Farzad Rahaghi is classified as an Elite expert for Pulmonary Hypertension, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Farzad Rahaghi specialize in?

While Dr. Farzad Rahaghi is a Pulmonary Medicine, they have specific expertise in Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency (AATD), and Interstitial Lung Disease. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pulmonary Medicine.

Does Dr. Farzad Rahaghi participate in research or clinical trials?

Yes. Dr. Farzad Rahaghi has published 46 articles and abstracts on conditions like Pulmonary Hypertension. You can view a list of Dr. Farzad Rahaghi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Farzad Rahaghi accept my insurance?

Dr. Farzad Rahaghi accepts most major insurance plans, including Aetna and AvMed. We recommend calling the office directly at 954-659-5450 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rahaghi's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 10 Advanced Conditions
View All 44 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile